Craig-Hallum analyst William Bonello maintained a Buy rating on GeneDx Holdings (WGS – Research Report) today. The company’s shares closed ...

STAMFORD, Conn. - GeneDx Holdings Corp. (NASDAQ:WGS), known for its genomic insights in healthcare and having achieved an impressive 2,342% return over the past year according to InvestingPro data, ...

GeneDx Holdings (NASDAQ:WGS) expects to exceed guidance with full year 2024 revenues of at least $299M ($288.20M estimate) and adjusted gross margin of at least 64% (previous guidance was at least ...

GeneDx Holdings Corp. (Nasdaq ... section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the ...

January 13, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for ...

--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq ... described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the ...

January 13, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the ...

GeneDx (WGS) Holdings eported preliminary financial results for the fourth quarter and full year of 2024. “2024 was a transformative year for GeneDx, as we achieved our profitability milestone ...

--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq ... other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 ...